VIP for Nerve Damage: Preclinical Signals on Vasoactive Intestinal Peptide
What's breaking down
The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.
Why VIP might help you
- Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- VIP → immune / autonomic
What the evidence actually shows
This is a count of what is in this ledger — not a claim about all research worldwide.
- Scientific sources catalogued (PubMed, trials, reviews): 4
- Claims tagged human evidence: 0
- Claims tagged preclinical (animal/lab): 4
- Claims tagged anecdotal: 0
- Reddit posts catalogued: 0
- X posts catalogued: 0
- Other anecdote sources (YouTube, Instagram, etc.): 0
- Total sources in chain: 4
Logic: Studies exist in the ledger, but none are graded as strong human proof for the uses people discuss online. Animal and lab work is not the same as proof in people.
Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.
Quantified confidence (this ledger): 0.26 / 1.00 — low — animal and anecdote heavy
Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.
What scientists say
Vasoactive intestinal peptide and nerve regeneration (source s1)
Rat study measuring VIP levels post-sciatic injury.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Chemically induced inflammation and nerve damage affect the distribution of VIP-LI structures (source s2)
Mentions VIP knockout effects in nerve injury model.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Vasoactive intestinal peptide protects against ischemic brain damage (source s3)
Rat ischemia study with VIP treatment.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
Studies of vasoactive intestinal polypeptide expression in sensory ganglia (source s4)
Human and animal expression data post-injury.
Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.
---
Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.
Evidence ledger 5 · tier-ranked · API
Ask this article · 7 suggested prompts
Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.